Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4588) 4588
Book Review (603) 603
Publication (167) 167
Newsletter (18) 18
Conference Proceeding (8) 8
Book Chapter (5) 5
Transcript (3) 3
Newspaper Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4266) 4266
humans (2667) 2667
male (2350) 2350
animals (2132) 2132
female (1729) 1729
epoprostenol - administration & dosage (1155) 1155
prostacyclin (1148) 1148
epoprostenol - pharmacology (1046) 1046
adult (991) 991
rats (977) 977
hypertension, pulmonary - drug therapy (944) 944
middle aged (932) 932
epoprostenol - therapeutic use (852) 852
abridged index medicus (830) 830
pulmonary hypertension (679) 679
epoprostenol - analogs & derivatives (670) 670
epoprostenol - biosynthesis (668) 668
cardiac & cardiovascular systems (558) 558
epoprostenol (534) 534
pharmacology & pharmacy (516) 516
aged (491) 491
epoprostenol - metabolism (485) 485
dose-response relationship, drug (479) 479
blood pressure - drug effects (464) 464
antihypertensive agents - administration & dosage (462) 462
hypertension, pulmonary - physiopathology (448) 448
respiratory system (434) 434
platelet aggregation - drug effects (414) 414
antihypertensive agents - therapeutic use (398) 398
hypertension (388) 388
therapy (387) 387
treatment outcome (383) 383
time factors (347) 347
dogs (342) 342
in vitro techniques (335) 335
hemodynamics - drug effects (326) 326
survival (319) 319
infusions, intravenous (318) 318
administration, inhalation (297) 297
pulmonary arterial hypertension (295) 295
rabbits (295) 295
nitric oxide (290) 290
iloprost (288) 288
indomethacin - pharmacology (276) 276
administration, oral (269) 269
peripheral vascular disease (268) 268
vasodilator agents - therapeutic use (263) 263
epoprostenol - blood (261) 261
rats, inbred strains (258) 258
drug therapy (256) 256
vasodilator agents - administration & dosage (256) 256
prostaglandins (250) 250
nitric-oxide (246) 246
epoprostenol - adverse effects (236) 236
surgery (232) 232
hypertension, pulmonary - etiology (229) 229
drug therapy, combination (225) 225
care and treatment (221) 221
treprostinil (221) 221
vascular resistance - drug effects (217) 217
mice (210) 210
continuous intravenous epoprostenol (209) 209
blood platelets - drug effects (198) 198
prostaglandins - pharmacology (198) 198
epoprostenol - physiology (197) 197
adolescent (195) 195
aspirin - pharmacology (192) 192
vasodilation - drug effects (191) 191
hypertension, pulmonary - diagnosis (189) 189
arterial-hypertension (188) 188
rats, sprague-dawley (187) 187
biochemistry & molecular biology (186) 186
bosentan (182) 182
endothelium (180) 180
cells, cultured (177) 177
medicine, general & internal (176) 176
rats, wistar (176) 176
hemodynamics (175) 175
research (175) 175
pregnancy (170) 170
endocrinology & metabolism (164) 164
vasodilator agents - pharmacology (164) 164
double-blind (163) 163
physiology (161) 161
endothelium, vascular - drug effects (160) 160
disease (157) 157
arachidonic acid (156) 156
heart rate - drug effects (155) 155
sildenafil (155) 155
platelet aggregation inhibitors - pharmacology (154) 154
6-ketoprostaglandin f1 alpha - blood (151) 151
double-blind method (151) 151
thromboxane b2 - blood (150) 150
endothelium, vascular - metabolism (149) 149
disease models, animal (148) 148
blood platelets - metabolism (146) 146
antihypertensive agents - adverse effects (142) 142
child (141) 141
inhaled nitric-oxide (140) 140
follow-up studies (138) 138
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4355) 4355
Japanese (71) 71
German (50) 50
French (32) 32
Russian (23) 23
Spanish (18) 18
Chinese (17) 17
Polish (17) 17
Italian (15) 15
Serbian (3) 3
Slovak (3) 3
Czech (2) 2
Danish (2) 2
Hungarian (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Turkish (2) 2
Dutch (1) 1
Korean (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial
by McLaughlin, Vallerie V and Benza, Raymond L and Rubin, Lewis J and Channick, Richard N and Voswinckel, Robert and Tapson, Victor F and Robbins, Ivan M and Olschewski, Horst and Rubenfire, Melvyn and Seeger, Werner
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 18, pp. 1915 - 1922
Objectives This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either... 
Treprostinil sodium | Inhalation therapy | Aerosol | Pulmonary heart disease | Pulmonary vascular disease | Prostacyclin | Pulmonary arterial hypertension | inhalation therapy | pulmonary heart disease | CARDIAC & CARDIOVASCULAR SYSTEMS | BRAIN NATRIURETIC PEPTIDE | SILDENAFIL | EFFICACY | prostacyclin | SAFETY | pulmonary vascular disease | COMBINATION | ILOPROST | INTRAVENOUS EPOPROSTENOL | DOUBLE-BLIND | pulmonary arterial hypertension | treprostinil sodium | aerosol | BOSENTAN | Piperazines - administration & dosage | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Purines - administration & dosage | Exercise Tolerance - drug effects | Sildenafil Citrate | Young Adult | Peptide Fragments - blood | Adult | Female | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Natriuretic Peptide, Brain - blood | Administration, Oral | Administration, Inhalation | Treatment Outcome | Epoprostenol - analogs & derivatives | Quality of Life | Aged | Vasodilator Agents - administration & dosage | Sulfonamides - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Hypertension | Studies | Pulmonary arteries | Collagen | Family medical history | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial
by Simonneau, Gérald and Rubin, Lewis J and Galiè, Nazzareno and Barst, Robyn J and Fleming, Thomas R and Frost, Adaani E and Engel, Peter J and Kramer, Mordechai R and Burgess, Gary and Collings, Lorraine and Cossons, Nandini and Sitbon, Olivier and Badesch, David B and PACES Study Grp and PACES Study Group
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug
by Corboz, Michel R and Li, Zhili and Malinin, Vladimir and Plaunt, Adam J and Konicek, Donna M and Leifer, Franziska G and Chen, Kuan-Ju and Laurent, Charles E and Yin, Han and Biernat, Marzena C and Salvail, Dany and Zhuang, Jianguo and Xu, Fadi and Curran, Aidan and Perkins, Walter R and Chapman, Richard W
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2017, Volume 363, Issue 3, pp. 348 - 357
This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-treprostinil (C16TR), a prodrug of treprostinil (TRE), formulated in... 
PROSTACYCLIN RECEPTOR | EP4 RECEPTOR | ANALOGS | ARTERIAL-HYPERTENSION | PHARMACOLOGY & PHARMACY | BINDING | ILOPROST | Antihypertensive Agents - pharmacology | Nanoparticles - chemistry | Vasodilator Agents - pharmacokinetics | Phosphatidylethanolamines - adverse effects | Humans | Excipients - adverse effects | Male | Polyethylene Glycols - chemistry | Squalene - analogs & derivatives | Drug Compounding | Hypertension, Pulmonary - drug therapy | Epoprostenol - pharmacokinetics | Guinea Pigs | Squalene - adverse effects | Antihypertensive Agents - therapeutic use | Excipients - administration & dosage | Rats, Sprague-Dawley | Epoprostenol - analogs & derivatives | Lung - drug effects | Vasodilation - drug effects | Phosphatidylethanolamines - chemistry | Drug Delivery Systems - adverse effects | Epoprostenol - administration & dosage | Prodrugs - administration & dosage | Epoprostenol - metabolism | Vasodilator Agents - therapeutic use | Antihypertensive Agents - administration & dosage | Polyethylene Glycols - adverse effects | Hypertension, Pulmonary - blood | Nanoparticles - adverse effects | Dose-Response Relationship, Drug | Epoprostenol - therapeutic use | Excipients - chemistry | Epoprostenol - pharmacology | Female | Lung - metabolism | Platelet Aggregation - drug effects | Drug Evaluation, Preclinical | Squalene - chemistry | Vasodilator Agents - pharmacology | Administration, Inhalation | Phosphatidylethanolamines - administration & dosage | Squalene - administration & dosage | Antihypertensive Agents - pharmacokinetics | Polyethylene Glycols - administration & dosage | Animals | Prodrugs - pharmacokinetics | Dogs | Nanoparticles - administration & dosage | Prodrugs - therapeutic use | Lung - blood supply | Prodrugs - pharmacology | Vasodilator Agents - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Upfront triple combination therapy in pulmonary arterial hypertension: A pilot study
by Sitbon, Olivier and Sitbon, Olivier and Jaïs, Xavier and Savale, Laurent and Cottin, Vincent and Bergot, Emmanuel and Bergot, Emmanuel and Macari, Elise Artaud and Bouvaist, Hél̀ene and Bouvaist, Hél̀ene and Dauphin, Claire and Dauphin, Claire and Picard, François and Bulifon, Sophie and Montani, David and Humbert, Marc and Simonneau, Gérald and Simonneau, Gérald
European Respiratory Journal, ISSN 0903-1936, 1791, Volume 43, Issue 6, pp. 1691 - 1697
Patients with severe pulmonary arterial hypertension (PAH) in New York Heart Association (NYHA) functional class (FC) III/IV have a poor prognosis, despite... 
SURVIVAL | IMPACT | SILDENAFIL | EPOPROSTENOL | TREPROSTINIL | RESPIRATORY SYSTEM | BOSENTAN | Piperazines - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Treatment Outcome | Purines - administration & dosage | Sildenafil Citrate | Young Adult | Drug Therapy, Combination - methods | Pilot Projects | Adolescent | Adult | Female | Registries | Aged | Hypertension, Pulmonary - drug therapy | Retrospective Studies | Sulfonamides - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): A randomized controlled trial
by Tapson, Victor F and Jing, Zhi-Cheng and Xu, Kai-Feng and Pan, Lei and Feldman, Jeremy and Kiely, David G and Kotlyar, Eugene and McSwain, C. Shane and Laliberte, Kevin and Arneson, Carl and Rubin, Lewis J and FREEDOM-C2 Study Team
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Background: Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy.... 
INHALED ILOPROST | SILDENAFIL | EFFICACY | RESPIRATORY SYSTEM | DOUBLE-BLIND | SUBCUTANEOUS INFUSION | BOSENTAN | CRITICAL CARE MEDICINE | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Phosphodiesterase 5 Inhibitors - administration & dosage | Familial Primary Pulmonary Hypertension | Treatment Outcome | Epoprostenol - analogs & derivatives | Adolescent | Aged | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Complications and side effects | Care and treatment | Patient outcomes | Treprostinil | Clinical trials | Dosage and administration | Research | Drug therapy | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Treatment of sarcoidosis-associated pulmonary hypertension: A two-center experience
by Barnett, Christopher F and Bonura, Eric J and Nathan, Steven D and Ahmad, Shahzad and Shlobin, Oksana A and Osei, Kwabena and Zaiman, Ari L and Hassoun, Paul M and Moller, David R and Barnett, Scott D and Girgis, Reda E
Chest, ISSN 0012-3692, 06/2009, Volume 135, Issue 6, pp. 1455 - 1461
Background: Pulmonary hypertension (PH) is a common complication of sarcoidosis that is associated with increased mortality. The pathogenesis of PH in... 
Prostacyclin | Bosentan | Sildenafil | Sarcoidosis | Pulmonary hypertension | STENOSIS | bosentan | prostacyclin | 6-MINUTE WALK TEST | RESPIRATORY SYSTEM | pulmonary hypertension | ARTERIAL-HYPERTENSION | DISEASE | sarcoidosis | sildenafil | HEMODYNAMICS | Piperazines - administration & dosage | Sarcoidosis - mortality | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Purines - administration & dosage | Hemodynamics - physiology | Sildenafil Citrate | Statistics, Nonparametric | Female | Hypertension, Pulmonary - drug therapy | Retrospective Studies | Drug Therapy, Combination | Severity of Illness Index | Hypertension, Pulmonary - mortality | Sarcoidosis - diagnosis | Iloprost - administration & dosage | Risk Assessment | Administration, Oral | Kaplan-Meier Estimate | Administration, Inhalation | Probability | Linear Models | Survival Rate | Treatment Outcome | Sarcoidosis - complications | Aged | Hemodynamics - drug effects | Respiratory Function Tests | Hypertension, Pulmonary - etiology | Sulfonamides - administration & dosage | Cohort Studies | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Index Medicus | Abridged Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension
by Ishihara, Tomoaki and Ishihara, Tsutomu and Hayashi, Erika and Yamamoto, Shuhei and Kobayashi, Chisa and Tamura, Yuichi and Tamura, Fumiya and Sawazaki, Ryoichi and Tahara, Kayoko and Kasahara, Tadashi and Takenaga, Mitsuko and Fukuda, Keiichi and Mizushima, Tohru
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 197, pp. 97 - 104
Prostaglandin I (PGI ) and its analogues (such as beraprost sodium, BPS) are beneficial for the treatment of pulmonary arterial hypertension (PAH). The... 
Encapsulation | Biodegradable nanoparticle | Pulmonary arterial hypertension | Prostaglandin I2 | Beraprost sodium | Prostaglandin I | SURVIVAL | RATS | VASCULAR-PERMEABILITY | CONTINUOUS INTRAVENOUS EPOPROSTENOL | BIODEGRADABLE NANOPARTICLES | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | THERAPY | Prostaglandin I-2 | PROSTACYCLIN ANALOG | NANOSPHERES | PHARMACOLOGY & PHARMACY | REGISTRY | Polymers - administration & dosage | Rhodamines - administration & dosage | Nanoparticles - chemistry | Rats, Wistar | Monocrotaline | Capillary Permeability - drug effects | Drug Carriers - administration & dosage | Delayed-Action Preparations - chemistry | Male | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Pulmonary Artery - metabolism | Delayed-Action Preparations - pharmacokinetics | Polyesters | Hypertension, Pulmonary - drug therapy | Rhodamines - chemistry | Lactic Acid - administration & dosage | Disease Models, Animal | Epoprostenol - pharmacokinetics | Lactic Acid - chemistry | Mice, Inbred C57BL | Hypertension, Pulmonary - metabolism | Pulmonary Artery - drug effects | Polyethylene Glycols - administration & dosage | Epoprostenol - analogs & derivatives | Animals | Epoprostenol - chemistry | Polymers - chemistry | Drug Carriers - pharmacokinetics | Nanoparticles - administration & dosage | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Epoprostenol - administration & dosage | Nanoparticles | Fluorescence | Models | Analysis | Pulmonary hypertension | Drugs | Drug delivery systems | Drug discovery | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension
by Akagi, Satoshi and Nakamura, Kazufumi and Matsubara, Hiromi and Kondo, Megumi and Miura, Daiji and Matoba, Tetsuya and Egashira, Kensuke and Ito, Hiroshi
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 04/2016, Volume 67, Issue 4, pp. 290 - 298
Nanoparticles (NPs) have been used as novel drug delivery systems. Drug-incorporated NPs for local delivery might optimize the efficacy and minimize the side... 
Prostacyclin | Pulmonary arterial smooth muscle cells | Drug delivery system | Nanomedicine | Pulmonary hypertension | Intratracheal administration | INHALED ILOPROST | SURVIVAL | SYSTEM | EPOPROSTENOL THERAPY | CARDIAC & CARDIOVASCULAR SYSTEMS | prostacyclin | pulmonary hypertension | nanomedicine | DELIVERY | intratracheal administration | AEROSOLIZED ILOPROST | pulmonary arterial smooth muscle cells | PHARMACOLOGY & PHARMACY | drug delivery system | Humans | Male | Hypertension, Pulmonary - prevention & control | Drug Delivery Systems | Hypertrophy, Right Ventricular - drug therapy | Cell Hypoxia | Nanoparticles | Young Adult | Pulmonary Artery - metabolism | Time Factors | Adult | Epoprostenol - pharmacology | Female | Hypertrophy, Right Ventricular - pathology | Myocytes, Smooth Muscle - drug effects | Child | Myocytes, Smooth Muscle - metabolism | Disease Models, Animal | Rats | Monocrotaline - toxicity | Pulmonary Artery - drug effects | Rats, Sprague-Dawley | Epoprostenol - analogs & derivatives | Animals | Adolescent | Cell Proliferation - drug effects | Epoprostenol - administration & dosage | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Initial dual oral combination therapy in pulmonary arterial hypertension
by Sitbon, Olivier and Sattler, Caroline and Bertoletti, Laurent and Savale, Laurent and Cottin, Vincent and Jaïs, Xavier and De Groote, Pascal and Chaouat, Ari and Chabannes, Céline and Bergot, Emmanuel and Bouvaist, Hélène and Dauphin, Claire and Bourdin, Arnaud and Bauer, Fabrice and Montani, David and Humbert, Marc and Simonneau, Gérald
European Respiratory Journal, ISSN 0903-1936, 06/2016, Volume 47, Issue 6, pp. 1727 - 1736
Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when... 
SURVIVAL | 2015 ESC/ERS GUIDELINES | DIAGNOSIS | MONOTHERAPY | EPOPROSTENOL | AMBRISENTAN | RESPIRATORY SYSTEM | SINGLE-CENTER | TADALAFIL | REGISTRY | BOSENTAN | Follow-Up Studies | Humans | Middle Aged | Familial Primary Pulmonary Hypertension - drug therapy | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Familial Primary Pulmonary Hypertension - physiopathology | Time Factors | Tadalafil - administration & dosage | Patient Safety | Pyridazines - administration & dosage | Adult | Female | Hypertension, Pulmonary - drug therapy | Retrospective Studies | Drug Therapy, Combination | Diethylpropion | Severity of Illness Index | Phenylpropionates - administration & dosage | Hypertension, Pulmonary - genetics | Treatment Outcome | Aged | Hemodynamics | Sildenafil Citrate - administration & dosage | Sulfonamides - administration & dosage | Index Medicus | Life Sciences | Bioengineering
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial
by Jing, Zhi-Cheng and Parikh, Keyur and Pulido, Tomas and Jerjes-Sanchez, Carlos and White, R. James and Allen, Roblee and Torbicki, Adam and Xu, Kai-Feng and Yehle, David and Laliberte, Kevin and Arneson, Carl and Rubin, Lewis J
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 624 - 633
Background-Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are... 
treprostinil | Exercise test | prostacyclin analogue | pulmonary arterial hypertension | SODIUM | CARDIAC & CARDIOVASCULAR SYSTEMS | INFUSION | exercise test | ILOPROST | THERAPY | PROSTACYCLIN ANALOG | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | CHINESE PATIENTS | INHALED TREPROSTINIL | BOSENTAN | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Incidence | Walking - physiology | Young Adult | Epoprostenol - therapeutic use | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Child | Administration, Oral | Familial Primary Pulmonary Hypertension | Treatment Outcome | International Cooperation | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Dyspnea - epidemiology | Epoprostenol - analogs & derivatives | Exercise Tolerance - physiology | Adolescent | Aged | Longitudinal Studies | Epoprostenol - administration & dosage | Treprostinil | Dosage and administration | Research | Drug therapy | Health aspects | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Meta‐analysis for the effect of medical therapy vs. Placebo on recovery of idiopathic sudden hearing loss
by Labus, Jakob and Breil, Judith and Stützer, Hartmut and Michel, Olaf
The Laryngoscope, ISSN 0023-852X, 09/2010, Volume 120, Issue 9, pp. 1863 - 1871
Objectives: To estimate the effect of recovery of idiopathic sudden hearing loss under placebo (first aim) and under medical therapy (second aim). Study... 
recovery under placebo | idiopathic | spontaneous recovery | Systematic review | sudden hearing loss | meta‐analysis | sudden deafness | medical therapy | Level of Evidence: 1a | rheological treatment | Sudden hearing loss | Idiopathic | Medical therapy | Recovery under placebo | Spontaneous recovery | Rheological treatment | Sudden deafness | Meta-analysis | MEDICINE, RESEARCH & EXPERIMENTAL | STEROIDS | meta-analysis | OTORHINOLARYNGOLOGY | DOUBLE-BLIND | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Follow-Up Studies | Administration, Oral | Humans | Controlled Clinical Trials as Topic | Epoprostenol - analogs & derivatives | Citrates - administration & dosage | Hearing Loss, Sudden - drug therapy | Procaine - administration & dosage | Infusions, Intravenous | Dextrans - administration & dosage | Pentoxifylline - administration & dosage | Epoprostenol - administration & dosage | Methylprednisolone - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial
by Tapson, Victor F and Torres, Fernando and Kermeen, Fiona and Keogh, Anne M and Allen, Roblee P and Frantz, Robert P and Badesch, David B and Frost, Adaani E and Shapiro, Shelley M and Laliberte, Kevin and Sigman, Jeffrey and Arneson, Carl and Galiè, Nazzareno
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 6, pp. 1383 - 1390
Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have... 
INHALED ILOPROST | TRANSITION | MULTICENTER | SILDENAFIL | RESPIRATORY SYSTEM | INTRAVENOUS EPOPROSTENOL | PROSTACYCLIN | DOUBLE-BLIND | INFECTION | SUBCUTANEOUS INFUSION | BOSENTAN THERAPY | CRITICAL CARE MEDICINE | Sulfones - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Walking - physiology | Dose-Response Relationship, Drug | Sildenafil Citrate | Young Adult | Epoprostenol - therapeutic use | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Familial Primary Pulmonary Hypertension | Treatment Outcome | Piperazines - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Epoprostenol - analogs & derivatives | Sulfonamides - therapeutic use | Exercise Tolerance - physiology | Adolescent | Aged | Epoprostenol - administration & dosage | Treprostinil | Dosage and administration | Research | Drug therapy | Patient outcomes | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
by Kumar, Parag and Thudium, Emily and Laliberte, Kevin and Zaccardelli, David and Nelsen, Andrew
Clinical pharmacokinetics, 12/2016, Volume 55, Issue 12, p. 1495
Treprostinil is available in three different formulations and four different routes of administration: Remodulin (treprostinil sodium, intravenous and... 
Drug Administration Routes | Epoprostenol - pharmacokinetics | Area Under Curve | Antihypertensive Agents - administration & dosage | Metabolic Clearance Rate | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Circadian Rhythm | Dose-Response Relationship, Drug | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Maximum Tolerated Dose | Drug Interactions | Hypertension, Pulmonary - drug therapy | Delayed-Action Preparations | Epoprostenol - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function
by Shimamura, Masahiro and Miyakawa, Jun and Doi, Masaaki and Okada, Kiyonobu and Kurumatani, Hajimu and Mori, Yoshitaka and Oshida, Keiyu and Nakajo, Ikumi and Oikawa, Keishi and Ushigome, Fumihiko and Miyashita, Aiji and Isono, Masanao and Miyamoto, Yohei
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2017, Volume 57, Issue 4, pp. 524 - 535
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS‐314 d , in Japanese subjects... 
TRK‐100STP | pharmacokinetics | beraprost sodium | chronic kidney disease | prostacyclin derivative | impaired kidney function | TRK-100STP | DOWN-REGULATION | PLASMA-PROTEIN BINDING | IN-VITRO | DRUG TRANSPORTERS | PROSTACYCLIN ANALOG | CHRONIC-HEMODIALYSIS | PRAVASTATIN SODIUM | PHARMACOLOGY & PHARMACY | TAMSULOSIN HYDROCHLORIDE | CHRONIC-RENAL-FAILURE | ACTIVE METABOLITE | Epoprostenol - pharmacokinetics | Administration, Oral | Humans | Middle Aged | Male | Renal Insufficiency - urine | Epoprostenol - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Female | Aged | Platelet Aggregation Inhibitors - pharmacokinetics | Renal Insufficiency - drug therapy | Renal Insufficiency - blood | Delayed-Action Preparations | Epoprostenol - administration & dosage | Protein Binding - physiology | Care and treatment | Chronic kidney failure | Pharmacokinetics | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Administration of prostacyclin modulates cutaneous blood flow but not sweating in young and older males: roles for nitric oxide and calcium‐activated potassium channels
by Fujii, Naoto and Notley, Sean R and Minson, Christopher T and Kenny, Glen P
The Journal of Physiology, ISSN 0022-3751, 11/2016, Volume 594, Issue 21, pp. 6419 - 6429
In young adults, cyclooxygenase (COX) contributes to the heat loss responses of cutaneous vasodilatation and sweating, and this may be mediated by... 
skin blood flow | ageing | IP receptor | cyclic adenosine monophosphate | prostanoids | heat loss | microcirculation | PHYSIOLOGY | ACETYLCHOLINE | TREPROSTINIL | DOWN-REGULATION | NEUROSCIENCES | EXERCISE | SYNTHASE | IONTOPHORESIS | RESPONSES | SMOOTH-MUSCLE | AGE-RELATED DECREMENTS | VASODILATION | Antihypertensive Agents - pharmacology | Skin - metabolism | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Nitric Oxide Synthase - antagonists & inhibitors | Male | Nitroarginine - pharmacology | Skin - blood supply | Sweating - drug effects | Regional Blood Flow - drug effects | Potassium Channels, Calcium-Activated - metabolism | Adult | Epoprostenol - pharmacology | Aged | Potassium Channels, Calcium-Activated - antagonists & inhibitors | Vasodilation - drug effects | Nitric Oxide - metabolism | Potassium Channel Blockers - pharmacology | Skin - drug effects | Epoprostenol - administration & dosage | Nitric oxide | Cyclic adenylic acid | Skin | Prostacyclin | Potassium channels | Adenylic acid | Blood flow | Aging | Young adults | Calcium | Rodents | Index Medicus | Integrative | Integrative Physiology | Research Paper | Cellular and Molecular Physiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights